World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
104
Citations
47406
World Ranking
6974
National Ranking
3668

Overview

Alan P. Venook is affiliated with the University of California, San Francisco in the United States. Their research primarily focuses on medicine, with a significant number of publications in oncology and cancer research. The subfields of study include oncology, cancer research, pulmonary and respiratory medicine, pathology and forensic medicine, and surgery.

The main topics covered in their work involve colorectal cancer treatments and studies, genetic factors in colorectal cancer, gastric cancer management and outcomes, cancer genomics and diagnostics, colorectal and anal carcinomas, colorectal cancer surgical treatments, and colorectal cancer screening and detection.

Alan P. Venook has contributed to numerous publications, with recent papers including:

  • Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology, 2021, Journal of the National Comprehensive Cancer Network
  • Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology, 2021, Journal of the National Comprehensive Cancer Network
  • Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology, 2022, Journal of the National Comprehensive Cancer Network
  • NCCN Guidelines Insights: Rectal Cancer, Version 6.2020, 2020, Journal of the National Comprehensive Cancer Network
  • Preoperative Treatment of Locally Advanced Rectal Cancer, 2023, New England Journal of Medicine

Frequent co-authors who have collaborated with Alan P. Venook include:

  • Heinz-Josef Lenz
  • Federico Innocenti
  • Fang-Shu Ou
  • Jeffrey A. Meyerhardt
  • Qian Shi

The scientist has published extensively in several venues, most notably:

  • Journal of Clinical Oncology
  • UNC Libraries
  • Journal of the National Comprehensive Cancer Network
  • The Oncologist
  • Clinical Cancer Research

Best Publications

  • Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival

    Francis Y. Yao;Linda Ferrell;Nathan M. Bass;Jessica J. Watson

  • NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

    Al B Benson;Thomas A. Abrams;Edgar Ben-Josef;P. Mark Bloomston

  • Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

    Ghassan K. Abou-Alfa;Tim Meyer;Ann Lii Cheng;Anthony B. El-Khoueiry

  • The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective

    Alan P. Venook;Christos Papandreou;Junji Furuse;Laura Ladrón de Guevara

  • Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

    Al B. Benson;Alan P. Venook;Mahmoud M. Al-Hawary;Mustafa A. Arain

  • Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

    Al B. Benson;Alan P. Venook;Lynette Cederquist;Emily Chan

  • NCCN Guidelines® Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines

    Al B Benson;Alan P. Venook;Mahmoud M. Al-Hawary;Lynette Cederquist

  • Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.

    D. Arnold;B. Lueza;J.-Y. Douillard;M. Peeters

  • Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial

    Alan P. Venook;Donna Niedzwiecki;Heinz Josef Lenz;Federico Innocenti

  • Rectal cancer, version 2.2018 clinical practice guidelines in Oncology

    Al B Benson;Alan P. Venook;Mahmoud M. Al-Hawary;Lynette Cederquist

  • NCCN Clinical Practice Guidelines in Oncology: colon cancer.

    Engstrom Pf;Arnoletti Jp;Benson Ab rd;Chen Yj

  • Hepatobiliary cancers, Version 2.2021

    Al B. Benson;Michael I. D'Angelica;Daniel E. Abbott;Daniel A. Anaya

  • NCCN Clinical Practice Guidelines in Oncology: rectal cancer.

    Engstrom Pf;Arnoletti Jp;Benson Ab rd;Chen Yj

  • Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-Mutant colorectal cancer

    Ryan B. Corcoran;Chloe E. Atreya;Gerald S. Falchook;Eunice L. Kwak

  • CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).

    Alan P. Venook;Donna Niedzwiecki;Heinz-Josef Lenz;Federico Innocenti

  • Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.

    Matthew H.G. Katz;Qian Shi;Syed A. Ahmad;Joseph M. Herman

  • American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes

    Lee M. Ellis;David S. Bernstein;Emile E. Voest;Jordan D. Berlin

  • Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid Syndrome

    Joseph Rubin;Jaffer Ajani;William Schirmer;Alan P. Venook

  • Hepatocellular Carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting

    Melanie B. Thomas;Deborah Jaffe;Michael M. Choti;Jacques Belghiti

  • Cetuximab in the treatment of colorectal cancer.

    Richard M Goldberg;Alan P Venook;Richard L Schilsky

Frequent Co-Authors

Donna Niedzwiecki
Donna Niedzwiecki Duke University
Jeffrey A. Meyerhardt
Jeffrey A. Meyerhardt Harvard University
Robert J. Mayer
Robert J. Mayer Dana-Farber Cancer Institute
Al B. Benson
Al B. Benson Northwestern University
Richard M. Goldberg
Richard M. Goldberg West Virginia University
Leonard Saltz
Leonard Saltz Memorial Sloan Kettering Cancer Center
Federico Innocenti
Federico Innocenti University of North Carolina at Chapel Hill
Robin Kate Kelley
Robin Kate Kelley University of California, San Francisco
Charles D. Blanke
Charles D. Blanke Oregon Health & Science University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

While a traditional MD is a unique path, there are many related online programs that can open doors to diverse healthcare careers. For example, if you’re interested in preventative medicine or working with patients on healthy lifestyle choices, a nutrition degree online can prepare you for roles in dietetics, food science, and wellness coaching.

Those drawn to healthcare leadership may prefer a cahme accredited online healthcare administration programs to gain skills in management, policy, and system improvement—without direct patient care. Nurses looking to advance can explore rn to bsn programs without clinicals, offering a flexible way to increase qualifications and job prospects from home.

For advanced nursing roles, fastest online dnp programs provide doctoral credentials at an accelerated pace. These diverse online pathways let you make meaningful contributions in healthcare, even if medical school isn’t your route.

Best Scientists Citing Alan P. Venook

Trending Scientists

Recently Published Articles